# A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Source: https://onco.cc/trials/nct07109726/  
OnCo record `nct07109726` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fulvestrant in endometrial cancer and ovarian cancer, run by Terremoto Biosciences Inc., now recruiting.

## Summary

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations is a phase 1/2 interventional study registered as NCT07109726 by Terremoto Biosciences Inc., with 205 participants planned, started 2025-09-23 and due to reach its primary completion in 2028-12-30. Interventions recorded: TER-2013, Fulvestrant injection. Conditions listed: Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07109726
- Phase: 1/2
- Setting: A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Sponsor: Terremoto Biosciences Inc.
- Enrolled: 205

## Sources

- ClinicalTrials.gov NCT07109726: https://clinicaltrials.gov/study/NCT07109726

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Fulvestrant](https://onco.cc/drugs/fulvestrant/)

---
JSON: https://onco.cc/api/v1/entities/nct07109726.json